合作
重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。
已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。
標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。
經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。
涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。
閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。
10月14日週三 · 今天
10月15日週四
7月23日週四
合作
合作
AMD and Cerebras announced a joint AI inference solution the companies describe as offering ultra-low latency and high throughput.
Accessibility: Skip TopNav AMD and Cerebras Announce Industry-Leading Ultra-Low-Latency and High Throughput AI Inference Solution July 23, 2026 13:45 ET | Source: Advanced Micro Devices, Inc. Advanced Micro Devices, Inc. News Highlights AMD and Cerebras are collaborating to advance a workload-optimized approach to ultra-low-latency AI inference infrastructure. AMD Helios™ and the Cerebras Wafer-Scale Engine will operate as a single disaggregated inference workflow, combining ultra-high-throughput from AMD Instinct™ GPUs, with ultra-fast token generation of Cerebras Wafer-Scale Engine. Cerebras…
合作
Amkor Technology announced a strategic partnership with NVIDIA to expand advanced packaging and test capacity for next-generation AI products.
7月22日週三
財報
Alphabet reported second-quarter 2026 revenue of $119.8 billion, up 24% year over year, with consolidated operating income up 30% to $40.8 billion and operating margin expanding two percentage points to 34%. Google Cloud revenue rose 82% to $24.8 billion. Capital expenditure was $44.9 billion for the quarter.
監管
The FDA granted priority review to Pfizer's combination of Talzenna and Xtandi in men with metastatic castration-sensitive prostate cancer whose tumours carry HRR mutations. Priority review shortens the FDA review period to six months from the standard 10 months. The application is supported by the Phase 3 TALAPRO-3 trial, in which the combination reduced the risk of radiographic progression or death by 52% versus placebo plus Xtandi.